argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvements in strength and quality…
Airwheel at Canton Fair 2026: Discover AI-Powered Luxury Rideable Electric 20inch Cabin Boarding Travel Smart Carry on Hand Suitcase
Avantor Expands RIM Single-Use Portfolio Across APAC
HKTDC backs new blueprint for Hong Kong’s next chapter
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops
Critical Minerals Minister Officially Opens GMG’s Gen 2.0 Graphene Manufacturing Plant